spacer
home > pmps > spring 2018 > supply network
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply Network

In an industry where the entire supply chain is faced with the regulatory requirement for serialisation and traceability, the solution needs large-scale integration and interoperability. For pharmaceutical businesses, the biggest challenge is how they orchestrate project implementation both internally and externally. In the Global Drug, Supply, Safety and Traceability report, just 48% of CMOs have integrated with a majority of brand owners, and just 41% of respondents stated that a high percentage of their internal packaging lines are ready for serialisation (1).

In every business, project leads must consider the overall complexity and scale of serialisation and traceability. They must understand and update internal processes and engage external partners before specifying and implementing a strategy and solution. While the pharma sector is well-versed at improving the performance of manufacturing and packing lines with new hardware and site-level systems, integrating with partners, each with their own policies and priorities, on the scale required by global serialisation and traceability is a completely new challenge. To complicate matters, the solution cannot be stationary – new products, partners, markets and regulations, customer requirements, and opportunities keep coming.

Managing all of these is hard work, but three core pillars of serialisation and traceability integration and interoperability in product supply networks can lead to success.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pasi Kemppainen is the Principal Advisor on pharma digitalisation at Epista Life Science. He is currently leading Santen Pharmaceutical’s global serialisation and traceability programme. Prior to Epista Life Science, Pasi worked as Senior Consultant and Advisor for NNE – a Novo Nordisk engineering and consulting company. He also served as CEO at Original1 (a joint venture of SAP, Nokia, and Giesecke & Devrient – leaders in enterprise IT, mobile, and security), servicing a cloud and mobile platform for product serialisation, traceability, and consumer authentication services in Europe and China.
spacer
Pasi Kemppainen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

4th Annual Genome Editing Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 4thAnnual Genome Editing Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement